(pp2025) root@inception:~/praxis# head -n 20 train_ds.jsonl
{"sentence": "RESULTS: Five hundred seventy-seven patients were randomly assigned: 192 to encorafenib plus binimetinib, 191 to vemurafenib, and 194 to encorafenib.", "aspect": "p", "keyphrases": {"sentence": 4, "kps": ["Five hundred seventy-seven patients", "192", "191", "194"]}}
{"sentence": "This study investigated the prognostic and predictive value of metformin, including with respect to BRAF mutation status, in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 randomised controlled trial.", "aspect": "rf", "keyphrases": {"sentence": 2, "kps": ["European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 randomised controlled trial"]}}
{"sentence": "METHODS: This multicentre, double-blind, randomised, controlled, phase 3 trial was done in 130 academic centres, community hospitals, and cancer centres across 25 countries.", "aspect": "b", "keyphrases": {"sentence": 2, "kps": ["double-blind"]}}
{"sentence": "Participating investigators randomly assigned (with an interactive voice response system) patients 2:1 to receive an intravenous infusion of nivolumab 3 mg/kg every 2 weeks or ICC (dacarbazine 1000 mg/m(2) every 3 weeks or paclitaxel 175 mg/m(2) combined with carboplatin area under the curve 6 every 3 weeks) until progression or unacceptable toxic effects.", "aspect": "r", "keyphrases": {"sentence": 4, "kps": ["an interactive voice response", "2:1"]}}
{"sentence": "Subsequently the anti-programmed cell death protein 1 (PD-1) antibodies, nivolumab and pembrolizumab were shown to be more effective than ipilimumab.", "aspect": "m", "keyphrases": {"sentence": 2, "kps": ["anti-programmed cell death protein 1 ( PD-1 ) antibodies", "nivolumab", "pembrolizumab"]}}
{"sentence": "METHODS: In this phase 3, multicenter, open-label trial, we randomly assigned patients with unresectable stage IIIC or IV melanoma in a 1:1 ratio to receive TIL or anti-cytotoxic T-lymphocyte antigen 4 therapy (ipilimumab at 3 mg per kilogram of body weight).", "aspect": "c", "keyphrases": {"sentence": 2, "kps": ["anti-cytotoxic T-lymphocyte antigen 4 therapy ( ipilimumab at 3 mg per kilogram of body weight )"]}}
{"sentence": "CONCLUSIONS: Among patients undergoing resection of stage IIIB, IIIC, or IV melanoma, adjuvant therapy with nivolumab resulted in significantly longer recurrence-free survival and a lower rate of grade 3 or 4 adverse events than adjuvant therapy with ipilimumab.", "aspect": "f", "keyphrases": {"sentence": 9, "kps": ["significantly longer recurrence-free survival", "a lower rate of grade 3 or 4 adverse events"]}}
{"sentence": "This trial assessed radiation therapy (RT) to the primary site after local excision.", "aspect": "i", "keyphrases": {"sentence": 1, "kps": ["radiation therapy ( RT ) to the primary site", "local excision"]}}
{"sentence": "Eight hundred nine patients were included, 240 treated with vemurafenib plus cobimetinib and 569 with vemurafenib.", "aspect": "p", "keyphrases": {"sentence": 2, "kps": ["Eight hundred nine patients", "240", "569"]}}
{"sentence": "At a median overall follow-up of 19·6 years (235 months, IQR 200-260), 621 deaths were reported-304 (49%) in the 2-cm group and 317 (51%) in the 4-cm group (unadjusted HR 0·98, 95% CI 0·83-1·14; p=0·75).", "aspect": "o", "keyphrases": {"sentence": 16, "kps": ["621 deaths", "reported-304", "49 %", "317", "51 %"]}}
{"sentence": "IFN-α-2b was administered at 3 million units three times a week subcutaneously for 24 weeks beginning at week 9.", "aspect": "i", "keyphrases": {"sentence": 6, "kps": ["3 million units three times a week", "24 weeks"]}}
{"sentence": "No statistically significant difference in RFS between stage III substage hazard ratios was observed per AJCC-7 or -8 staging criteria (interaction test: AJCC-7, P = 0.8115; AJCC-8, P = 0.1051; P = 0.8392 ((AJCC-7) and P = 0.8678 (AJCC-8) for DMFS).", "aspect": "o", "keyphrases": {"sentence": 6, "kps": ["No statistically significant difference in RFS between stage III substage hazard ratios was observed per AJCC-7 or -8 staging criteria ( interaction test : AJCC-7 , P = 0.8115 ; AJCC-8 , P = 0.1051 ; P = 0.8392 ( ( AJCC-7 ) and P = 0.8678 ( AJCC-8 ) for DMFS )"]}}
{"sentence": "Treatment was given open-label, but those doing tumour assessments were masked to treatment assignment.", "aspect": "b", "keyphrases": {"sentence": 8, "kps": ["open-label"]}}
{"sentence": "Treatment with combined ipilimumab and nivolumab yielded high response rates (RECIST ORR 73%, pCR 45%) but substantial toxicity (73% grade 3 trAEs), whereas treatment with nivolumab monotherapy yielded modest responses (ORR 25%, pCR 25%) and low toxicity (8% grade 3 trAEs).", "aspect": "o", "keyphrases": {"sentence": 3, "kps": ["RECIST ORR 73 %", "pCR 45 %", "73 % grade 3 trAEs", "ORR 25 %", "pCR 25 %", "8 % grade 3 trAEs"]}}
{"sentence": "We conducted an adjuvant trial of sequential, low-dose dacarbazine (DTIC) and interferon-alpha-2b (IFN-α-2b) in patients with cytogenetic high-risk uveal melanoma.", "aspect": "m", "keyphrases": {"sentence": 2, "kps": ["low-dose dacarbazine ( DTIC )", "interferon-alpha-2b ( IFN-α-2b )"]}}
{"sentence": "METHODS: In this double-blind study involving 142 patients with metastatic melanoma who had not previously received treatment, we randomly assigned patients in a 2:1 ratio to receive ipilimumab (3 mg per kilogram of body weight) combined with either nivolumab (1 mg per kilogram) or placebo once every 3 weeks for four doses, followed by nivolumab (3 mg per kilogram) or placebo every 2 weeks until the occurrence of disease progression or unacceptable toxic effects.", "aspect": "c", "keyphrases": {"sentence": 1, "kps": ["ipilimumab", "placebo", "placebo"]}}
{"sentence": "The 35 vaccine recipients were then randomized to receive one month of high-dose IFNα or observation.", "aspect": "p", "keyphrases": {"sentence": 3, "kps": ["35 vaccine recipients"]}}
{"sentence": "No treatment-related deaths were reported.", "aspect": "ae", "keyphrases": {"sentence": 10, "kps": ["No treatment-related deaths"]}}
{"sentence": "PATIENTS AND METHODS: In a double-blind, phase 3 trial (NCT02388906), patients aged ≥15 years with resected, histologically confirmed AJCC-7 stage IIIB, IIIC, or IV melanoma were randomised to receive nivolumab 3 mg/kg every 2 weeks or ipilimumab 10 mg/kg every 3 weeks for 4 doses and then every 12 weeks, both intravenously ≤1 year.", "aspect": "td", "keyphrases": {"sentence": 2, "kps": ["every 2 weeks", "for 4 doses and then every 12 weeks", "≤1 year"]}}
{"sentence": "RESULTS: Median follow-up on February 18, 2019, was 16.3 months in PEM200+IPI50 (N = 51) and 16.4 months in PEM200+IPI100 (N = 51).", "aspect": "fd", "keyphrases": {"sentence": 5, "kps": ["16.3 months", "16.4 months"]}}
(pp2025) root@inception:~/praxis# 